GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharmaron Beijing Co Ltd (HKSE:03759) » Definitions » Capex-to-Revenue

Pharmaron Beijing Co (HKSE:03759) Capex-to-Revenue : 0.17 (As of Sep. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Pharmaron Beijing Co Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

Pharmaron Beijing Co's Capital Expenditure for the three months ended in Sep. 2024 was HK$-604.33 Mil. Its Revenue for the three months ended in Sep. 2024 was HK$3,537.45 Mil.

Hence, Pharmaron Beijing Co's Capex-to-Revenue for the three months ended in Sep. 2024 was 0.17.


Pharmaron Beijing Co Capex-to-Revenue Historical Data

The historical data trend for Pharmaron Beijing Co's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharmaron Beijing Co Capex-to-Revenue Chart

Pharmaron Beijing Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Capex-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.20 0.26 0.28 0.29 0.25

Pharmaron Beijing Co Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Capex-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.25 0.21 0.19 0.15 0.17

Competitive Comparison of Pharmaron Beijing Co's Capex-to-Revenue

For the Biotechnology subindustry, Pharmaron Beijing Co's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pharmaron Beijing Co's Capex-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pharmaron Beijing Co's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where Pharmaron Beijing Co's Capex-to-Revenue falls into.



Pharmaron Beijing Co Capex-to-Revenue Calculation

Pharmaron Beijing Co's Capex-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-3134.028) / 12620.016
=0.25

Pharmaron Beijing Co's Capex-to-Revenue for the quarter that ended in Sep. 2024 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-604.333) / 3537.453
=0.17

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Pharmaron Beijing Co  (HKSE:03759) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.


Pharmaron Beijing Co Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of Pharmaron Beijing Co's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Pharmaron Beijing Co Business Description

Traded in Other Exchanges
Address
No. 248 Queen’s Road East, 40th Floor, Dah Sing Financial Centre, Wanchai, Hong Kong, HKG
Pharmaron Beijing Co Ltd is a research and development service company supporting the life science industry. The company offers drug research and development service capabilities, ranging from synthetic, medicinal, and analytical chemistry, biology, DMPK, pharmacology, drug safety assessment, radiochemistry and isotopically labelled metabolism, chemical and pharmaceutical development to clinical development. The company's operating segment includes Laboratory services; CMC (small molecule CDMO) services; Clinical development services and biologics and CGT services. It generates maximum revenue from the Laboratory services segment.
Executives
Morgan Stanley 2201 Interest of corporation controlled by you
Jpmorgan Chase & Co. 2201 Interest of corporation controlled by you
The Bank Of New York Mellon Corporation 2201 Interest of corporation controlled by you
Citigroup Inc. 2201 Interest of corporation controlled by you
Blackrock, Inc. 2201 Interest of corporation controlled by you
Gic Private Limited 2102 Investment manager
The Capital Group Companies, Inc. 2201 Interest of corporation controlled by you
Matthews International Capital Management, Llc 2102 Investment manager
First H Share Award And Scheme Of Pharmaron Beijing Co., Ltd. 2301 Trustee
Kastle Limited 2301 Trustee
Jian Xin Bei Jing Tou Zi Ji Jin Guan Li You Xian Ze Ren Gong Si 2201 Interest of corporation controlled by you
Jian Xin Xin Tuo You Xian Ze Ren Gong Si 2201 Interest of corporation controlled by you

Pharmaron Beijing Co Headlines

No Headlines